Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.41 |
| ▸ | KIF11 | P52732 | 3/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | CPA3 | P15088 | 1/20 | 0.39 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | MME | P08473 | 1/20 | 0.38 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL342180 | 1.00 | CYP1A2 (0.41) | CYP1A2KIF11CYP2D6CPA3FOLH1 | |
| SCHEMBL335641 | 0.84 | KIF11 (0.52) | CYP1A2KIF11KMT2A | |
| SCHEMBL27713868 | 0.79 | LMNA (0.44) | CYP1A2KIF11CYP2D6SRCMAPT | |
| SCHEMBL9373145 | 0.78 | MAPT (0.45) | CYP1A2KIF11CYP2D6MAPTKMT2A | |
| SCHEMBL1235122 | 0.78 | KMT2A (0.48) | CYP1A2KIF11CYP2D6SRCMAPT | |
| SCHEMBL6505750 | 0.74 | CYP1A2 (0.39) | CYP1A2KIF11CYP2D6CPA3FOLH1 | |
| SCHEMBL4579475 | 0.73 | CYP1A2 (0.48) | CYP1A2KIF11CYP2D6SRCMAPT | |
| SCHEMBL29351710 | 0.73 | KIF11 (0.48) | CYP1A2KIF11CYP2D6MAPTKMT2A | |
| SCHEMBL34784 | 0.72 | FOLH1 (0.48) | CYP1A2KIF11CPA3FOLH1 | |
| SCHEMBL3785507 | 0.72 | FOLH1 (0.48) | CYP1A2KIF11CPA3FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10556933-B2 | Polypeptide libraries with a predetermined scaffold | AFFIBODY AB (SE) | 2020-02-11 | — | — | US | disclosed |
| US-20170008936-A1 | Polypeptide Libraries With A Predetermined Scaffold | AFFIBODY AB (SE) | 2017-01-12 | — | — | US | disclosed |
| US-9469670-B2 | Polypeptide libraries with a predetermined scaffold | AFFIBODY AB (SE) | 2016-10-18 | — | — | US | disclosed |
| EP-1996609-B1 | METHOD OF PREPARING GLYCOPEPTIDES | SCRIPPS RESEARCH INST (US) | 2016-08-03 | — | — | EP | disclosed |
| US-8883120-B2 | Polypeptides having affinity for HER2 | AFFIBODY AB (SE) | 2014-11-11 | — | — | US | disclosed |
| US-8816050-B2 | Method of preparing glycopeptides | THE SCRIPPS RESEARCH INSTITUTE | 2014-08-26 | — | — | US | disclosed |
| US-20130280164-A1 | POLYPEPTIDES HAVING AFFINITY FOR HER2 | AFFIBODY AB (SE) | 2013-10-24 | — | — | US | disclosed |
| EP-2235044-B1 | NEW POLYPEPTIDES HAVING AFFINITY FOR HER2 | AFFIBODY AB (SE) | 2013-10-09 | — | — | EP | disclosed |
| US-8501909-B2 | Polypeptides having affinity for HER2 | AFFIBODY AB (SE) | 2013-08-06 | — | — | US | disclosed |
| EP-1924275-B1 | THIO-CONTAINING INHIBITORS OF AMINOPEPTIDASE P, COMPOSITIONS THEREOF AND METHOD OF USE | SIMMONS WILLIAM H (US) | 2012-08-08 | — | — | EP | disclosed |
| US-20030153736-A1 | Labelled ascorbic acid derivatives | GE HEALTHCARE LIMITED (GB) | 2003-08-14 | — | — | US | disclosed |
| EP-1239886-A2 | LABELLED ASCORBIC ACID DERIVATIVES | GE Healthcare Limited (GB) | 2002-09-18 | — | — | EP | disclosed |
| WO-2002062819-A2 | BACKBONE CYCLIZED RADIOLABELLED SOMATOSTATIN ANALOGS | PEPTOR LTD. (IL) | 2002-08-15 | — | — | WO | disclosed |
| US-20020077306-A1 | CONJUGATES MADE OF METAL COMPLEXES AND OLIGONUCLEOTIDES, AGENTS CONTAINING THE CONJUGATES, THEIR USE IN RADIODIAGNOSIS AS WELL AS PROCESS FOR THEIR PRODUCTION | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2002-06-20 | — | — | US | disclosed |
| US-6342201-B1 | COMPLEXES WHICH ENRICH ARTERIOSCLEROTIC PLAQUE AND ARE PREFERENTIALLY SUITED FOR NON-INVASIVE DIAGNOSIS OF ARTERIOSCLEROSIS | INSTITUT FOR DIAGNOSTIKFORSCHUNG GMBH AN DER FREIEN UNIVERSITAT (DE) | 2002-01-29 | — | — | US | disclosed |
| WO-2001047564-A2 | LABELLED ASCORBIC ACID DERIVATIVES | AMERSHAM PLC (GB) | 2001-07-05 | — | — | WO | disclosed |
| EP-0777498-A1 | CONJUGATES MADE OF METAL COMPLEXES AND OLIGONUCLEOTIDES | SCHERING AKTIENGESELLSCHAFT (DE) | 1997-06-11 | — | — | EP | disclosed |
| WO-1996002274-A1 | CONJUGATES MADE OF METAL COMPLEXES AND OLIGONUCLEOTIDES | SCHERING AKTIENGESELLSCHAFT (DE) | 1996-02-01 | — | — | WO | disclosed |
| US-4999424-A | Antigout and antitumor agents | THE PENNSYLVANIA STATE UNIVERSITY (US) | 1991-03-12 | — | — | US | disclosed |
| WO-1990005137-A1 | GAR TRANSFORMYLASE INHIBITOR | THE PENNSYLVANIA RESEARCH CORPORATION (US) | 1990-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020077306-A1 | CONJUGATES MADE OF METAL COMPLEXES AND OLIGONUCLEOTIDES, AGENTS CONTAINING THE CONJUGATES, THEIR USE IN RADIODIAGNOSIS AS WELL AS PROCESS FOR THEIR PRODUCTION | DCLRE1B, RNASE1, DCLRE1A | CYP1A2 4573/4885KIF11 1428/4885CYP2D6 3912/4885 |
| US-20030153736-A1 | Labelled ascorbic acid derivatives | CYP27B1, CYP24A1, XDH | CYP1A2 789/4885KIF11 3724/4885CYP2D6 790/4885 |
| US-20130280164-A1 | POLYPEPTIDES HAVING AFFINITY FOR HER2 | IGF2BP1, IGF2BP2, ERBB2 | CYP1A2 4782/4885KIF11 1733/4885CYP2D6 4610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.